Danielle Campbell
Human Resources Officer at ATYR PHARMA, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Gergen | M | 61 | 6 years | |
| Sanjay Shukla | M | 52 | 8 years | |
| Paul Schimmel | M | 83 | 19 years | |
| Tim Coughlin | M | 57 | 7 years | |
| John Clarke | M | 70 | 19 years | |
| Harry Leonhardt | M | 67 | 4 years | |
| Sarah Thailing | F | - | 4 years | |
| Ashlee Dunston | F | - | 4 years | |
| Luke Corning | M | 41 | 4 years | |
| Svetlana Lucas | M | 52 | 5 years | |
| Jane Gross | M | 67 | 5 years | |
| Kristin Martin | F | 49 | 5 years | |
| Leslie Nangle | M | - | - | |
| Nancy Krueger | F | 56 | 10 years | |
| Sara Zaknoen | M | 65 | 3 years | |
| John Schmid | M | 61 | 6 years | |
| Marcea Lloyd | F | 75 | 5 years | |
| Jill Broadfoot | F | 63 | 6 years | |
| Robert W. Ashworth | M | - | 3 years | |
| Andrew B. Cubitt | M | - | 13 years | |
| Richard Heyman | M | 66 | - | |
| Karen Basbaum | F | - | 4 years | |
| Lisa Portale | F | - | 5 years | |
| Peter Villiger | M | - | 8 years | |
| Lisa Carey | F | - | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Cleveland | M | 67 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 1 years |
| Krisztina Zsebo | M | 68 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 11 years |
| Nishan de Silva | M | 51 | 3 years | |
| Patrick Yang | M | 75 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 1 years |
| Catherine Mackey | M | 68 | 2 years | |
| Tiago Girão | M | 44 |
Cytori Therapeutics, Inc.
 Cytori Therapeutics, Inc. BiotechnologyHealth Technology Cytori Therapeutics, Inc. develops treatments and devices for cell therapy. The private company is based in San Diego, CA. | 5 years |
| Grove Matsuoka | M | - | - | |
| David Hirsch | M | 53 | 4 years | |
| Matthew A. Spear | M | 57 | 6 years | |
| Debra Gessner | F | - | - | |
| Sanuj K. Ravindran | M | - | 1 years | |
| Kerry Ingalls | M | - | 3 years | |
| Glenn Dourado | M | - | - | |
| Sean Murphy | M | 71 | 3 years | |
| John McKew | M | 59 | 2 years | |
| Ashraf Amanullah | M | 56 | 3 years | |
| Stephen Connelly | M | 42 | 2 years | |
| Paiman Peter Ghoroghchian | M | - | 3 years | |
| Naresh K. Nayyar | M | - | 2 years | |
| Jeff Knight | M | 52 | 3 years | |
| Patrick Johnson | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 46 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Danielle Campbell
- Personal Network
